News

August 30, 2019
APRINOIA Therapeutics has Initiated a Collaboration with Keio University in Tokyo, Japan
APRINOIA Therapeutics has initiated a collaboration with Keio University in Tokyo, Japan to profile patients with dementia using APRINOIA’s tau PET imaging tracer, 18F-APN-1607 (PM-PBB3). The collaboration is a part of the EKID (Eisai-Keio Innovation Laboratory for Dementia) study conducted by Keio University and Eisai Co. Ltd., which is supported by a research grant (No. JP17pc0101006) from AMED (Japan Agency for Medical Research and Development). APRINOIA is grateful for the opportunity to contribute to the study which might be useful for deeper understanding of dementia, especially Alzheimer’s Disease.
July 1, 2019
APRINOIA Therapeutics Selected and Joined JLABS @ Shanghai

May 23, 2019
APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers. ​APRINOIA has established a proprietary small molecule platfo...

March 26, 2019
2019 Taiwan Top 10 Coolest Tech Startups

Dr. Liang-Gee Chen, Minister of Ministry of Science and Technology (MOST), announced the 10 coolest tech startup companies today at Taiwan Tech Arena (TTA). The Taiwan government has invested the resources in building a tech startup ecosystem in Taiwan, this policy has encouraged many startups come up with innovative ideas and solution to emerged into the market. This year, the Ministry of Scie...

December 28, 2018
2019 Human Amyloid Imaging Conference Participation

December 25, 2018
APRINOIA Licenses Tau PET Imaging Tracer APN-1607 to Celgene

APRINOIA Therapeutics, a clinical-stage biotechnology company developing therapeutics and diagnostic imaging tools for neurodegenerative diseases, announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [  F]-labeled positron emission tomography (PET) imaging tracer, to suppo...

October 12, 2018
Emerging Company Profile – APRINOIA TACKLES TAU

September 1, 2018
APRINOIA Will Participate Asia-China: 2018 Clinical Trials on Alzheimer’s Disease Conference
APRINOIA will sponsor the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.
January 16, 2018
APRINOIA Closed US$11.1 Million Series B Financing

APRINOIA Therapeutics Inc., a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, announces today the completion of its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (T...

December 15, 2017
APRNIOIA Will participate 2018 Human Amyloid Imaging Conference
APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.